- Refer a
patient
Meet the Care Team
Our Programs
Cancer Survivorship
Developmental Therapeutics Program
Pediatric Oncology
Pediatric Musculoskeletal Tumor Program
Young Women’s Blood Disorders Program
Pediatric Stem Cell Transplant Program
Cancer Susceptibility Program
Pediatric Hematology
Pediatric Brain Tumor Program
Bleeding Disorders Treatment Program
Pediatric Sickle Cell Disease Program
Conditions We Treat
Pediatric cancer
Pediatric ependymoma
Pediatric extramedullary hematopoiesis
Pediatric medulloblastoma
Retinoblastoma in Children
Sarcomas in children
Pediatric glioblastoma
Leukemia in children
Pediatric lymphoma
Pediatric neurofibromatosis (NF)
Rhabdomyosarcoma in children
Pediatric bleeding disorders and thrombosis
Pediatric hemarthrosis
Pediatric benign bone tumors and cysts
Pediatric genitourinary cancer
Pediatric neuroblastoma
Pediatric Ewing sarcoma
Pediatric osteosarcoma
Non-rhabdomyosarcoma soft tissue sarcoma in children
Osteochondroma in children
Pediatric aneurysmal bone cysts (ABC)
Pediatric Wilms tumor (nephroblastoma)
More Details
Other Featured Clinical Trials
Check out some of our clinical trials:
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Latest News
Patrick Leavey, M.D., became Associate Director of Clinical Research at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.
Ayesha Zia, M.D., Pediatric Hematologist/Oncologist at Children’s Health and Associate Professor at UT Southwestern, has been appointed as the Associate Vice Chair of Clinical Research for the Department of Pediatrics at UT Southwestern.
Laura Klesse, M.D., Pediatric Hematologist/Oncologist at Children's Health and Associate Professor at UT Southwestern, was named a Principal Investigator for the Pediatric Early Phase Clinical Trials Network.
Conferences and Events
Many of our conferences and events offer continuing education credits.
Save the date for the 2024 ASPHO Conference April 3-6, 2024 in Seattle, WA.